R&D | April 29, 2026
Evonik and Higuchi launch “Open Pharma Lab” in Yokohama to accelerate oral drug Innovation
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
The approval was driven by data from the Phase III TULIP-SC trial
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
